Targacept, a developer of a new class of drugs to treat Alzheimer's and cognitive loss, priced 5.0 million shares at $9 Monday evening, below its original $11 to $13 range. Deutsche Bank and Pacific Growth Equities were the lead managers on the deal. Expect the stock to begin trading on the Nasdaq this morning under the symbol "TRGT."
